Cyclic alpha-MSH analog
A cyclic alpha-MSH analog with both skin pigmentation and sexual response effects, sold as a research chemical with significant safety concerns.
Abstract
Melanotan II (MT-II; CAS 121062-08-6; molecular formula C50H69N15O9; molecular weight 1024.18) is a cyclic heptapeptide alpha-MSH analog developed at the University of Arizona in parallel with Melanotan I. The compound shows higher receptor affinity than the linear Melanotan I but with non-selective melanocortin receptor activity (MC1, MC3, MC4, MC5). The clinical effect profile combines the skin pigmentation of MC1 activation with the sexual response effects of MC4 activation; this dual activity led to development of the more selective bremelanotide for sexual function applications and sustained pigmentation via Melanotan I. Melanotan II is not approved by any regulatory authority and is sold as a research chemical with significant safety concerns: the non-selective receptor activity produces reliable adverse events including nausea, flushing, blood pressure elevation, and concerning case reports of melanocyte dysplasia and atypical mole development. The compound should be regarded as substantially more hazardous than the more selective marketed melanocortin agonists.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.